# to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction

> **NCT05162261** · NA · COMPLETED · sponsor: **Novoxel Ltd.** · enrollment: 109 (actual)

## Conditions studied

- Meibomian Gland Dysfunction
- Dry Eye Syndromes
- Dry Eye

## Interventions

- **DEVICE:** Tixel C
- **DEVICE:** LipiFlow

## Key facts

- **NCT ID:** NCT05162261
- **Lead sponsor:** Novoxel Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-19
- **Primary completion:** 2023-04-26
- **Final completion:** 2023-09-28
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05162261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05162261, "to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05162261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*